|
|
|
|
|
|||||||
|
Session 63
Poster Session
Drug-Drug Interactions 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 440-W. | Pharmacokinetic Interaction between Lopinavir/r and Amprenavir in Salvage Therapy C. Solas*1, A. M. Quinson2, C. Couprie1, I. Ravaux2, I. Poizot-Martin3, A. Durand1, and B. Lacarelle1 1Timone Hosp., 2Conception Hosp., and 3Sainte-Marguerite Hosp., Marseille, France
| ||
| 441-W. | Pharmacokinetics, Efficacy, and Safety of Once-Daily Saquinavir-sgc plus Low-Dose Ritonavir (1200/100 mg) in Combination with Efavirenz in HIV-Pretreated Patients L. F. López-Cortés, P. Viciana, R. Ruiz-Valderas, R. Contreras, and A. Alarcón* Hosp. Univ. Virgen del Rocío, Sevilla, Spain
| ||
| 442-W. | Amprenavir is an Effective Inducer of Delavirdine Metabolism: A Steady-State Pharmacokinetic Interaction Study between Amprenavir and Delavirdine in Healthy Volunteers U. Justesen*1, N. Klitgaard2, K. Brosen1, and C. Pedersen2 1Univ. of Southern Denmark, Odense and 2Odense Univ. Hosp., Denmark
| ||
| 443-W. | Evaluation of Steady-State Interaction between Atazanavir (ATV) and Efavirenz (EFV) S. Preston*1, P. Piliero1, E. O'Mara2, V. Mummaneni2, D. Randall2, C. Morvillo1, M. Geraldes2, S. Agarwala2, and G. Drusano1 1Albany Med. Coll., NY and 2Bristol-Myers Squibb Pharamceutical Res. Inst., Princeton, NJ
| ||
| 444-W. | Steady-State Pharmacokinetic Interaction Study of Atazanavir (ATV) with Efavirenz (EFV) and Ritonavir (RTV) in Healthy Subjects E. O'Mara*1, S. Agarwala1, D. Randall1, M. Geraldes1, R. Stoltz2, and V. Mummaneni1 1Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ and 2GFI, Inc., Evansville, IN
| ||
| 445-W. | Pharmacokinetic (PK) Effect of Rifabutin (RIF) on Atazanavir (ATV) with and without Ritonavir (RTV) in Healthy Subjects S. Agarwala*1, V. Mummaneni1, D. Randall1, M. Geraldes1, R. Stoltz2, and E. O'Mara1 1Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ and 2GFI, Inc., Evansville, IN
| ||
| 446-W. | Pravastatin 40-mg qd Does not Alter Protease Inhibitor (PI) Exposure or Virological Efficacy over 24 Weeks Therapy G. J. Moyle*1, N. E. Buss2, and B. Gazzard1 1Chelsea and Westminster Hosp., London, UK and 2Roche, Basel, Switzerland
| ||
| 447-W. | Pharmacokinetics (PK) of Lower Doses of Saquinavir Soft Gel Caps (SQV) (800- and 1200-mg BID) with Itraconazole (Itra) Compared to 1400 mg SQV BID without Itra in HIV-1+ Thai Patients P. Cardiello*1,2, T. Samor1 , D. Burger3, R. Hoetelmans4, A. Mahanontharit1, K. Ruxrungtham1,5, J. Lange2 , D. A. Cooper6, and P. Phanuphak1 1HIVNET; 2IATEC, Amsterdam;3UMC, Nijmegen, 4Slotervaart Hosp., Amsterdam, The Netherlands; 5Chulalongkorn Univ., Bangkok, Thailand; and 6NCHECR, Univ. of New South Wales, Australia
| ||
| 448-W. | Nelfinavir Unbound Drug Interactions and Protein Binding Characteristics F. Aweeka*1, T. Motoya2, L. Thevanayagam1, T. Blaschke3, J. Stone1, A. Jayewardene1, and J. Chi1 1Univ. of California, San Francisco; 2Kagoshima Univ., Japan; and 3Stanford Univ., CA
|
